BioNTech’s Endometrial ADC Data Is Not a Science Story — It’s a $3 Billion Market Access Problem in Disguise
Trastuzumab pamirtecan just posted compelling Phase 2 numbers in HER2-expressing recurrent endometrial cancer. The science is clean. The commercial...